Preliminary results for treatments in subacute sclerosing panencephalitis have problems?
Anlar
Banu
B
D000998:Antiviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016527:Drug Costs; D006801:Humans; D007542:Inosine Pranobex / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D019259:Lamivudine / Q000627:therapeutic use*; D011994:Recombinant Proteins; D015203:Reproducibility of Results; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D013344:Subacute Sclerosing Panencephalitis / Q000188:drug therapy*; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D007542:Inosine Pranobex